ARCT vs BBIO
ARCT: Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue while advancing pipeline programs for rare genetic diseases. BBIO: BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization.
Side-by-side fundamentals
| Metric | ARCT | BBIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.93 | $82.66 | |
| Market cap as of 2026-07-23 | $168M | $16.2B | |
| PEG as of 2026-07-23 | -0.18 | -3.61 | BBIO lower |
| Net margin as of 2026-07-23 | -143.8% | -124.4% | BBIO higher |
| Gross margin as of 2026-07-23 | n/a | +95.1% | |
| Operating margin as of 2026-07-23 | -161.5% | -90.5% | BBIO higher |
| ROE as of 2026-07-23 | -36.5% | -206.7% | ARCT higher |
| ROA as of 2026-07-23 | -28.4% | -65.8% | ARCT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 8.27 | ARCT lower |
| Revenue growth (YoY) as of 2026-07-23 | -61.9% | +355.2% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | -26.4% | +86.3% | BBIO higher |
| Beta as of 2026-07-23 | 2.28 | 0.97 | |
| 1-year return as of 2026-07-22 close | -56.6% | +79.6% | BBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.